 HomeProductsAPI ImpurityDapagliflozin Impurity 39 CAS 864070-18-8

Contact Supplier

Ms. Lily

Leave a message

Contact Now

Dapagliflozin Impurity 39 CAS 864070-18-8

Name: Dapagliflozin Impurity 39 CAS 864070-18-8
Brand: Shandong Bolode Bio-technology Co., Ltd.
Price: 1 USD
Rating: 4.4 (18 reviews)

$1

≥1
Gram

Payment Type:

L/C,T/T,D/P,D/A,Paypal,Others

Incoterm:

CFR,CIF,FOB

Min. Order:

1 Gram

Transportation:

Ocean,Land,Air,Express,Others

Port:

jinan,shanghai,beijing

Contact Now

Product Description

Supply Ability & Additional Information
Packaging & Delivery
Company Overview
Company Photos
Product Image

< >

Overview

Supply Ability & Additional Information

Packaging: brown vial + Aluminum foil bag +box(Package as customer's requirements)

Transportation: Ocean,Land,Air,Express,Others

Supply Ability: in stock

Port: jinan,shanghai,beijing

Payment Type: L/C,T/T,D/P,D/A,Paypal,Others

Incoterm: CFR,CIF,FOB

Packaging & Delivery

Selling Units:: Gram

Package Type:: brown vial + Aluminum foil bag +box(Package as customer's requirements)

Picture Example:

Dapagliflozin (ForxigaTM) is a new type of anti-diabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca, which was approved by the European Medicines Agency (EMA) on November 12, 2012. The first SGLT2 inhibitor approved for the treatment of type 2 diabetes, which can be used as an important option in the treatment of diabetes drugs and can be used as a supplementary diet and exercise to improve blood sugar control in adults with type 2 diabetes. Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, was approved by the U.S. Food and Drug Administration (FDA) on January 8, 2014, for the treatment of type 2 diabetes. Postmarketing trials required by the FDA include a cardiovascular outcomes trial to assess cardiovascular risk in patients at high risk for cardiovascular disease at baseline after treatment with dapagliflozin and a study to assess bladder cancer risk in recruited patients. Another study will evaluate the drug's bladder tumor-promoting effect in rodents. Two studies will evaluate the pharmacokinetics, efficacy and safety of dapagliflozin in pediatric patients; an enhanced pharmacovigilance program will monitor liver abnormalities and reports of pregnancy outcomes in patients receiving dapagliflozin.

4-(5-broMo-2-chlorobenzyl)phenol

864070-18-8

C15H14Cl2O

Product Categories : API Impurity

Company Overview

Shandong Bolode Bio-technology Co., Ltd. Is specializing in R&D, production and sales of various chemical products. Our dominant products are impurities ，custom synthetic compounds，APIs and pharmaceutical intermediates,. We serve drug research both for domestic and worldwide . Our products have been sold to many countries including USA, India, South Korea, South America, Europe and so on.

Company Photos

Product Image

Hot Products

Email to this supplier

*Subject:
*To:

Ms. Lily
*Email:
*Message:

Your message must be between 20-8000 characters